I'm not sure what was witty, but don't mind being as sharp as a...

I'm not sure what was witty, but don't mind being as sharp as a knife.
I think in the context of the 17th April announcement the poor performance of the placebo is not going to raise any questions, as the bases are covered quite well. Also there was a sign that the placebo arm had lower diagnosed anxiety/depression than the active arm, so it may be the depression/anxiety issues were not being as carefully monitored by their physicians, or the patients families were not aware it was a problem to treat. It is also possibly a seasonal effect - kids happier in the lead up to Christmas, than afterwards? Whatever the case, the results are still very strong.

"At commencement of the Phase II/III ASD trial, 62% of patients in the NTI164 arm were receiving
treatment for their anxiety/depression and 43% of patients in the placebo arm. Between day 0 and
the end of week 8, patients in the placebo arm saw a deterioration of 24% in their ADAMS result (+7.50)
and for NTI164, there was a 39% improvement (-19.9) from baseline to the end of week 8. "